Old Web
English
Sign In
Acemap
>
authorDetail
>
Ted Szatrowski
Ted Szatrowski
Bristol-Myers Squibb
Immunology
Medicine
Oncology
Tyrosine-kinase inhibitor
Imatinib
3
Papers
1316
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
2010
The New England Journal of Medicine
Hagop M. Kantarjian
Neil P. Shah
Andreas Hochhaus
Jorge E. Cortes
Sandip Shah
Manuel Ayala
Beatriz Moiraghi
Zhixiang Shen
Jiri Mayer
Ricardo Pasquini
Hirohisa Nakamae
Françoise Huguet
Concepción Boqué
Charles Chuah
Eric Bleickardt
M. Brigid Bradley-Garelik
Chao Zhu
Ted Szatrowski
David Shapiro
Michele Baccarani
Show All
Source
Cite
Save
Citations (1299)
Opportunistic Infections Are Uncommon with Dasatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).
2009
Blood
Ali M Al-Ameri
Hagop M. Kantarjian
Gautam Borthakur
Erkut Bahceci
Ted Szatrowski
Andrew Damokosh
Jorge E. Cortes
Show All
Source
Cite
Save
Citations (12)
A Phase I/II Study of the Oral mTOR Inhibitor RAD001 in Patients with Advanced Hematologic Malignancies
2004
Journal of Immunotherapy
Karen Yee
Susan OBrien
William G. Wierda
Deborah A. Thomas
Razelle Kurzrock
Luis Fayad
Fredrick B. Hagemeister
Andre Goy
Jorge E. Cortes
Judith Prestifilippo
Ted Szatrowski
Hagop M. Kantarjian
Francis J. Giles
Show All
Source
Cite
Save
Citations (5)
1